Cited by 595Parkinson's Disease Mechanisms and TreatmentsAutophagy in Disease and TherapyAlzheimer's disease research and treatments

Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases

Open access
Spencer, Brian, Potkar, Rewati, Trejo, Margarita, Rockenstein, Edward, Patrick, Christina, Gindi, Ryan, Adame, Anthony, Wyss-Coray, Tony +1 more·2009·The Journal of Neuroscience

Abstract

Accumulation of the synaptic protein α-synuclein (α-syn) is a hallmark of Parkinson's disease (PD) and Lewy body disease (LBD), a heterogeneous group of disorders with dementia and parkinsonism, where Alzheimer's disease and PD interact. Accumulation of α-syn in these patients might be associated with alterations in the autophagy pathway. Therefore, we postulate that delivery of beclin 1, a regulator of the autophagy pathway, might constitute a strategy toward developing a therapy for LBD/PD. Overexpression of α-syn from lentivirus transduction in a neuronal cell line resulted in lysosomal accumulation and alterations in autophagy. Coexpression of beclin 1 activated autophagy, reduced accumulation of α-syn, and ameliorated associated neuritic alterations. The effects of beclin 1 overexpression on LC3 and α-syn accumulation were partially blocked by 3-MA and completely blocked by bafilomycin A1. In contrast, rapamycin enhanced the effects of beclin 1. To evaluate the potential effects of activating autophagy in vivo, a lentivirus expressing beclin 1 was delivered to the brain of a α-syn transgenic mouse. Neuropathological analysis demonstrated that beclin 1 injections ameliorated the synaptic and dendritic pathology in the tg mice and reduced the accumulation of α-syn in the limbic system without any significant deleterious effects. This was accompanied by enhanced lysosomal activation and reduced alterations in the autophagy pathway. Thus, beclin 1 plays an important role in the intracellular degradation of α-syn either directly or indirectly through the autophagy pathway and may present a novel therapeutic target for LBD/PD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.4390-09.2009

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Masliah E Rockenstein E Veinbergs I Mallory M Hashimoto M Takeda A Sagara Y Sisk A Mucke L Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders Science 2000b 287 1265 1269 10678833

Cited by

Sorted by citations

Authors
Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., & Masliah, E.
Affiliations
University of California San Diego (US)
Corresponding author
Masliah, Eliezer
Venue
The Journal of Neuroscience
Published
2009-10-28
Volume
29
Issue
43
Pages
13578-13588
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2088198588
Cited by
595
References
72
Citations by year
2026: 10 · 2025: 23 · 2024: 19 · 2023: 30 · 2022: 29 · 2021: 29 · 2020: 41 · 2019: 58 · 2018: 35 · 2017: 42 · 2016: 36 · 2015: 55 · 2014: 44 · 2013: 47 · 2012: 42
FWCI
20.70
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (AG5131, AG‐022074, AG‐18440, AG10435)
  • National Institute on Aging (P01AG010435, R37AG018440, R01AG018440, P50AG005131, AG-5131, AG022074, AG 18440, R01AG030144, P01AG022074, AG10435)
  • National Institute of Environmental Health Sciences (P01ES016738)
  • National Center for Research Resources (P41RR004050)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Beclin-1, alpha-synuclein, Parkinson's disease, Lewy body disease, autophagy, lysosomal accumulation, LC3, bafilomycin A1, rapamycin, 3-methyladenine, transgenic mouse model, synaptic pathology, limbic system, neurodegeneration
MeSH terms
Beclin-1, Animals, Autophagy, Brain, Disease Models, Animal, Humans, Mice, Transgenic, Nerve Degeneration, Neurons, Parkinson Disease, Signal Transduction, Gene Transfer Techniques, Lewy Body Disease, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, Rats, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review